Please enable JS

Investors & Media

OVERVIEW

The mission of CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. In addition to our fully-owned programs, we have established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases with high unmet need. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. We are headquartered in Basel, Switzerland with R&D operations in Cambridge, Massachusetts, USA and some business operations in London, United Kingdom.


Corporate Presentation

Preview of Module presentationsArchiveAudioColumn01.3
CRISPR Therapeutics Corporate Presentation

Recent News

CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China
CRISPR Therapeutics to Present at the JMP Securities Life Sciences Conference
CRISPR Therapeutics Appoints James R. Kasinger as General Counsel

View More






Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet